PLANET
Panitumumab
+ FOLFOX4
(n = 26)
Panitumumab
+ FOLFIRI
(n = 21)
ETS < 20%
≥ 20%
ETS < 20%
≥ 20%
N (%)
6 (23.1)
20 (
76.1
)
4 (19.1)
17 (
80.9
)
Median PFS, months
(95% CI)
3.1 (1.4
‒
12.8)
14.2
(9.9
‒
26.7)
13.4 (4.1
‒
18.7)
14.9
(7.1
‒
27.0)
HR (95% CI)
P-value
0.17 (0.06
‒
0.50)
0.001
0.62 (0.17
‒
2.28)
0.468
Panitumumab + FOLFOX4 / FOLFIRI (n = 47)
ETS < 20%
ETS ≥ 20%
Median OS, months
(95% CI)
26.5 (6.5, 39.0)
51.5 (35.1, 51.5)
HR (95% CI)
P-value
0.31 (0.11-0.83)
0.020
PRIME
Panitumumab + FOLFOX4
ETS < 20%
≥ 20%
n (%)
†
61 (28)
158
(
72
)
Median PFS, months
(95% CI)
6.7 (5.4–9.9)
13.6
(12.0–15.7)
HR (95% CI)
P-value
0.62 (0.45–0.85)
0.0031
Median OS, months (95%
CI)
12.6
(9.3–18.2)
32.5
(28.3–37.6)
HR (95% CI)
P-value
0.47 (0.34–0.65)
< 0.0001
ETS y su asociación con SLP y SG
